Comirnaty (tozinameran - Pfizer/BIONTECH) in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed COVID (any severity)detailed results C4591031- first boost, 2021 (REV) 18.52 [7.91; 43.34]
18.52 [7.91 ; 43.34 ] C4591031- first boost, 2021 (REV) 1 0% 10,125 NA not evaluable severe COVID-19 (FDA definition)detailed results C4591031- first boost, 2021 (REV) 4.03 [0.18; 89.41]
4.03 [0.18 ; 89.41 ] C4591031- first boost, 2021 (REV) 1 0% 10,125 NA not evaluable severe COVID-19 occurrencedetailed results C4591031- first boost, 2021 (REV) 4.03 [0.18; 89.41]
4.03 [0.18 ; 89.41 ] C4591031- first boost, 2021 (REV) 1 0% 10,125 NA not evaluable arrhythmiadetailed results C4591031- first boost, 2021 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable hypertensiondetailed results C4591031- first boost, 2021 (REV) 2.01 [0.07; 60.05]
2.01 [0.07 ; 60.05 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable Myocardial infarction detailed results C4591031- first boost, 2021 (REV) 1.34 [0.30; 6.00]
1.34 [0.30 ; 6.00 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable pulmonary embolismdetailed results C4591031- first boost, 2021 (REV) 6.04 [0.30; 120.71]
6.04 [0.30 ; 120.71 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed results C4591031- first boost, 2021 (REV) 1.01 [0.06; 16.10]
1.01 [0.06 ; 16.10 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results C4591031- first boost, 2021 (REV) 2.01 [0.07; 60.05]
2.01 [0.07 ; 60.05 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable appendicitisdetailed results C4591031- first boost, 2021 (REV) 0.25 [0.01; 5.58]
0.25 [0.01 ; 5.58 ] C4591031- first boost, 2021 (REV) 1 0% 10,075 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 01:03 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 758
- roots T: 290